MedTrace Logo

Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

NCT02995096 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23124

Last updated 2019-04-02

No results posted yet for this study

Summary

Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population. In addition to tumor characteristics, It has been suggested that pre-treatment and sirolimus-based immunosuppression may affect recurrence and survival. With data from the European Liver Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival after liver transplantation for HCC.

Conditions

  • Liver Transplantation

Interventions

PROCEDURE

Pre-treatment

Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)

DRUG

Sirolimus based immunosuppression

Immunosuppression regimens containing Sirolimus

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Hans-Christian Pommergaard, MD, PhD · Dept. of Surgery and Transplantion, Rigshospitalet, Denmark

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-10-31
Completion
2019-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02995096 on ClinicalTrials.gov